Patents Assigned to INPROTHER APS
  • NUCLEIC ACIDS ENCODING HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) ENVELOPE PROTEINS CONTAINING MODIFIED IMMUNOSUPPRESSIVE DOMAINS (ISD) AND USES THEREOF
    Publication number: 20260077031
    Abstract: A vaccine for use in the prophylaxis and/or treatment of a disease The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: July 11, 2025
    Publication date: March 19, 2026
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • Nucleic acids encoding human endogenous retrovirus K (HERV-k) envelope proteins containing modified immunosuppressive domains (ISD) and uses thereof
    Patent number: 12390522
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 19, 2025
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20250186579
    Abstract: A vaccine for use in the prophylaxis and/or treatment of a disease The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: February 21, 2025
    Publication date: June 12, 2025
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • Vaccine for use in the prophylaxis and/or treatment of a disease
    Patent number: 12263214
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: January 16, 2024
    Date of Patent: April 1, 2025
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • Vaccine for use in the prophylaxis and/or treatment of a disease
    Patent number: 12023377
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: July 2, 2024
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20240148860
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 9, 2024
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • Vaccine for use in the prophylaxis and/or treatment of a disease
    Patent number: 11883487
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: January 30, 2024
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20230181716
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: August 30, 2019
    Publication date: June 15, 2023
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20220387580
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 8, 2022
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20220347291
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: April 28, 2022
    Publication date: November 3, 2022
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH
  • Vaccine for use in the prophylaxis and/or treatment of a disease
    Patent number: 11351247
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 7, 2022
    Assignee: INPROTHER APS
    Inventors: Peter Holst, Christian Thirion, Lasse Neukirch
  • A VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE
    Publication number: 20200330586
    Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.
    Type: Application
    Filed: August 30, 2018
    Publication date: October 22, 2020
    Applicant: INPROTHER APS
    Inventors: Peter HOLST, Christian THIRION, Lasse NEUKIRCH